Similar articles

• Cardiovascular disease and toxicities related to HIV infection and its therapies.

  Zareba KM, Miller TL, Lipshultz SE. Zareba KM, et al. Expert Opin Drug Saf. 2005 Nov;4(6):1017-25. doi: 10.1517/14740338.4.6.1017. Expert Opin Drug Saf. 2005. PMID: 16255661 Review.
• Growing up with perinatal HIV infection: time for a HAART to heart.

  Siberry GK, Joyner M, Hutton N. Siberry GK, et al. J Pediatr. 2008 Oct;153(4):456-7. doi: 10.1016/j.jpeds.2008.05.049. J Pediatr. 2008. PMID: 18847617 No abstract available.
• HAART to heart: highly active antiretroviral therapy and the risk of cardiovascular disease in HIV-infected or exposed children and adults.

  Lipshultz SE, Mas CM, Henkel JM, Franco VI, Fisher SD, Miller TL. Lipshultz SE, et al. Expert Rev Anti Infect Ther. 2012 Jun;10(6):661-74. doi: 10.1586/eri.12.53. Expert Rev Anti Infect Ther. 2012. PMID: 22734956 Review.
• Dyslipidaemia and cardiovascular risk in HIV infection.

  Kulasekaram R, Peters BS, Wierzbicki AS. Kulasekaram R, et al. Curr Med Res Opin. 2005 Nov;21(11):1717-25. doi: 10.1185/030079905X65529. Curr Med Res Opin. 2005. PMID: 16307691 Review.
• First Italian consensus statement on diagnosis, prevention and treatment of cardiovascular complications in HIV-infected patients in the HAART era (2006).

  Carosi G, Quiros-Roldan E, Torti C, Antinori A, Bevilacqua M, Bonadonna RC, Bonfanti P, Castagna A, Cauda R, d'Arminio-Monforte A, Di Gregorio P, Di Perri G, Esposito R, Fatuzzo F, Gervasoni C, Giannattasio C, Guaraldi G, Lazzarin A, Lo Caputo S, Maggi P, Mazzotta F, Moroni M, Prestileo T, Ranieri R, Rizzardini G, Russo R, Galli M; Members of the Italian Cardiovascular Risk Guidelines Working Group. Carosi G, et al. Infection. 2007 Jun;35(3):134-42. doi: 10.1007/s15010-007-6295-5. Infection. 2007. PMID: 17565453